Virulence factor made by influenza virus is potential target for vaccine drug development

A new study describes how NS1, a protein produced by influenza A viruses, suppresses the body's immune responses to viral infection. Researchers present the potential to develop a live attenuated vaccine based on an engineered influenza A virus lacking NS1 and to design antiviral drugs that target NS1. The study is published in Journal of Interferon & Cytokine Research (JICR).

In the article entitled "Interactions Between NS1 of Influenza A Viruses and Interferon-α/β: Determinants for Vaccine Development," coauthors Ben Wang and Eleanor Fish, University Health Network and University of Toronto, Canada, examine the body's first line of defense against infectious agents such as viruses—the interferon (IFN)-α/ß response. The researchers describe the effects of IFN-α/ß on influenza A virus replication, how NS-1 inhibits IFN-α/ß production, and the potential for using IFN-α/ß or blocking NS-1 activity as a treatment for influenza A virus infection.

"Influenza viruses remain a major cause of human morbidity and mortality. This article suggests potential new approaches to combat these viruses," says Journal of Interferon & Cytokine Research Co-Editor-in-Chief Ganes C. Sen, Department of Immunology, Cleveland Clinic Foundation, Cleveland, OH.


Explore further

Oral interferon may prevent and control avian influenza virus infection

More information: Ben X. Wang et al, Interactions Between NS1 of Influenza A Viruses and Interferon-α/β: Determinants for Vaccine Development, Journal of Interferon & Cytokine Research (2017). DOI: 10.1089/jir.2017.0032
Citation: Virulence factor made by influenza virus is potential target for vaccine drug development (2017, August 14) retrieved 18 July 2019 from https://medicalxpress.com/news/2017-08-virulence-factor-influenza-virus-potential.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more